Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 21, Issue 1, 2009, Pages 15-24

  Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Cytoreductive surgery; Hyperthermia; Intraperitoneal chemotherapy; Peritoneal cancer index; Peritonectomy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; MITOXANTRONE; PACLITAXEL;

ADVANCED CANCER; APPENDIX TUMOR; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; OVARY CANCER; PARENTERAL NUTRITION; PERIOPERATIVE PERIOD; PERITONEUM; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERIOPERATIVE CARE; PERITONEUM; PROGNOSIS;

EID: 59149084292     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32831f8f32     Document Type: Review

References (42)

1. SEER incidence: AA rates for white/black/other, 1973-2001. Surveillance, Epidemiology and End Results Program. National Cancer Institute; 2001.
2. US estimated complete prevalence counts on 1/1/2001. Surveillance, Epidemiology and End Results Program. National Cancer Institute; 2001.
3. SEER 12 registries incidence and mortality (2003 Submission). Surveillance, Epidemiology and End Results Program. National Cancer Institute; 2001.
4. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841.
5. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705-2712.
6. Sampson J. Implantation peritoneal carcinomatosis of ovarian origin. J Pathol 1931; VII:423-443.
7. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22:465-472.
8. Delgado G, Chun B, Caglar H, Bepko F. Paraaortic lymphadenectomy in gynecologic malignancies confined to the pelvis. Obstet Gynecol 1977; 50:418-423.
9. Markman M, Bundy BN, Alberts DS, et al., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-1007.
10. Alberts DS, Liu PY, Hannigan EV, et al., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclopho-sphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950- 1955.
11. Armstrong DK, Bundy B, Wenzel L, et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34-43.
12. Gonzalez Bayon L, Sugarbaker PH, Gonzalez Moreno S, et al., Initiation of a program in peritoneal surface malignancy. Surg Oncol Clin N Am 2003; 12:741-753.
13. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49- 58.
14. Young R, Perez C, Hoskins W. Cancer of the ovary. In: DeVita VT, Hellman S, Steven A Rosenberg, editors. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott; 1993. pp. 1226.
15. Zang RY, Zhang ZY, Li ZT, et al., Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 2000; 26:798-804.
16. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003; 13:764- 770.
17. Morris RJ, Woodcock JP. Evidence-based compression: prevention of stasis and deep vein thrombosis. Ann Surg 2004; 239:162-171.
18. De Lima Vazquez V, Sugarbaker PH. Total anterior parietal peritoneotomy. J Surg Oncol 2003; 83:261 -263.
19. Esquivel J, Farinetti A, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed. G Chir 1999; 20:81-86.
20. Sugarbaker PH. Peritoneotomy procedures. Ann Surg 1995; 221:29-42.
21. Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1998; 7:83-90.
22. Takahashi I, Emi Y, Hasuda S, et al., Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 2002; 131:S78-S84.
23. Jacquet P, Averbach A, Stuart OA, et al., Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998; 41:147-154.
24. Markman M, Rowinsky E, Hakes T, et al., Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10:1485- 1491.
25. van der Vange N, van Goethem AR, Zoetmulder FA, et al., Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26:663-668.
26. Steller MA, Egorin MJ, Trimble EL, et al., A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43:106-114.
27. Nicoletto MO, Padrini R, Galeotti F, et al., Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000; 45:457-462.
28. Deraco M, Rossi CR, Pennacchioli E, et al., Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001; 87:120-126.
29. Sugarbaker PH. Early postoperative intraperitoneal adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: drugs and diseases. Boston: Kluwer; 1996. pp. 15-30.
30. Ozols RF, Locker GY, Doroshow JH, et al., Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209-3214.
31. Los G, Sminia P, Wondergem J, et al., Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27:472-477.
32. Panteix G, Geaujard A, Garbit F, et al., Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22:1329-1336.
33. Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 2005; 92:142-146.
34. Kuh H, Jang SH, Wientjes MG, et al., Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999; 290:871-880.
35. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003; 52:405-410.
36. Stuart OA, Knight C, Sugarbaker PH. Avoiding carcinogen exposure with intraperitoneal paclitaxel. Oncol Nurs Forum 2005; 32:44-48.
37. Tentes AA, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003; 29:69-73.
38. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007; 18:1943-1950. This systematic review brings together in a single place, all of the data that would support the use of cytoreductive surgery with HIPEC for the management of carcinomatosis.
39. Yan TD, Zappa L, Edwards G, et al., Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for nonappendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 2007; 96:102-112. This study presents the morbidity and mortality that is associated with cytoreductive surgery and intraperitoneal chemotherapy for patients with ovarian cancer. The study is important in that it establishes an acceptable complication rate for this advanced treatment strategy.
40. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007; 14:484-492.
41. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7:69-76.
42. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727-731.